Drug Trial Radar · NCT06392009
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 10, 2024
Primary completion
Jun 2026
Study completion Jun 2028
Sponsor
- Lead sponsor
- GRIN Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study RAD-GRIN-201 is a phase 1B/2A trial to assess safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type II. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A and one year in Part B/long-term treatment period. The treatment period in Part B may be extended based on a favorable benefit/risk profile.
Conditions
- Tuberous Sclerosis Complex
- Focal Cortical Dysplasia
Interventions
RadiprodilDrug
Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Adverse Drug Reactions (ADRs), TEAEs Leading to Discontinuation and Severity of TEAEsTime frame: from Baseline to End-of-study: 1 year 6 months
- Plasma concentration of radiprodil and maximum plasma concentration (Cmax)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
- Plasma concentration of radiprodil versus time, area under the curve (AUCt)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
- Pharmacokinetic plasma concentration of radiprodil: half-life (T1/2)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
- Pharmacokinetic plasma concentration of radiprodil: time to Cmax (Tmax)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
- Pharmacokinetic plasma concentration of radiprodil, clearance (Cl)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
- Number of participants with abnormal laboratory tests resultsTime frame: from Baseline to End-of-study: 1 year 6 months
- Number of participants with abnormal physical and neurological examination findingsTime frame: Baseline, MV7, and in Part B: Month 3, 6, 9, 12: week 6, week 28, week 40, week 52, week 64, week 76
- Clinically relevant changes in safety parameters: systolic blood pressureTime frame: from Baseline to End-of-study: 1 year 6 months
- Clinically relevant changes in safety parameters: diastolic blood pressureTime frame: from Baseline to End-of-study: 1 year 6 months
- Clinically relevant changes in safety parameters: pulse rateTime frame: from Baseline to End-of-study: 1 year 6 months
- 12-Lead ECG: Mean change from Baseline to End-of-Treatment in RR intervalTime frame: from Baseline to End-of-study: 1 year 6 months
- 12-Lead ECG: Mean change from Baseline to End-of-Treatment in PR intervalTime frame: from Baseline to End-of-study: 1 year 6 months
- 12-Lead ECG: Mean change from Baseline to End-of-Treatment in QRS intervalTime frame: from Baseline to End-of-study: 1 year 6 months
- 12-Lead ECG: Mean change from Baseline to End-of-Treatment in QT intervalTime frame: from Baseline to End-of-study: 1 year 6 months
- 12-Lead ECG: Mean change from Baseline to End-of-Treatment in QTcF intervalTime frame: from Baseline to End-of-study: 1 year 6 months
Locations
18 sites in 8 countries. Site status is shown where the registry gives one.
Queensland Children Hospital
South Brisbane, Australia
University Hospitals Leuven, Pediatric Neurology
Leuven, Belgium
Alberta Children's Hospital
Calgary, Canada
The Hospital for Sick Children (Sick Kids)
Toronto, Canada
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Roma, Italy
Universita Cattolica del Sacro Cuore - Policlinico Universitario "Agostino Gemelli"
Roma, Italy
IRCCS Istituto Giannina Gaslini
Genoa, Liguria, Italy
AOU Meyer
Florence, Tuscany, Italy
UMC Uthrecht - Wilhelmina Kinderziekenhuis
Utrecht, Netherlands
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Centrum Medyczne Plejady
Krakow, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu
Poznan, Poland
Instytut Pomnik - Centrum Zdrowia Dziecka
Warsaw, Poland
Hospital Universitario Vall D´Hebrón
Barcelona, Spain
Hospital Materno Infantil Sant Joan de Deu de Barcelona
Barcelona, Spain
Hospital Universitario Vithas La Milagrosa
Madrid, Spain
Hospital Ruber Internacional
Madrid, Spain
University Hospitals Bristol and Weston NHS Foundation Trust Bristol Royal Hospital for Children
Bristol, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.